Gilboa Therapeutics to Present at the H.C. Wainwright 
BioConnect 2022 Conference

​

Presentation to Include an Update on SolidT Therapeutics Program, IND-Enabling

Studies and Clinical Trial Plan

​

SAN DIEGO (PRWEB) JANUARY 06, 2022

​

Gilboa Therapeutics Inc., a preclinical-stage biopharmaceutical company focused on the discovery and development of next-generation cell therapies, today announced that’s its Chief Executive Officer, David Pyrce, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.

​

Gilboa's CEO will provide a corporate update on the company’s SolidT cell therapy platform,

as well as the Company’s pipeline of multiple SolidT-based product candidates advancing through IND-enabling studies with clinical studies planned for 2023.

 

Details for this presentation are as follows:

​

H.C. Wainwright BioConnect 2022 Conference
Conference Dates: January 10-13, 2022
Presentation: Available online upon start of conference on Monday, January 10, 2022
Format: Virtual conference; on-demand webcast

​

The presentation will be available on the H.C. Wainwright website, https://hcwevents.com, 
as well as on the Gilboa website at https://www.gilboa.bio/.

 

About Gilboa Therapeutics

​

Gilboa Therapeutics is a preclinical-stage biopharmaceutical company focused on the development of novel and high-impact, 
next-generation cancer immunotherapies designed to harness the power of a patient’s own immune system to treat cancer, improve outcomes and save lives. While immunotherapies have improved outcomes for some patients, unfortunately, many patients do not respond to currently available therapies. At Gilboa, our mission is to enable more patients to respond, as well as improve response rates, by applying our game-changing approach to fighting cancer. Our proprietary technology, SolidT, is an engineered cell therapy, intended to be used in combination with a wide range of antigen-specific antibodies, enabling the targeting of multiple different tumor types. Recognizing the significant, unmet medical need, we are driven by a sense of urgency to discover, develop and rapidly bring our game-changing new therapeutics to cancer patients in need, significantly improve outcomes and save lives. This is our promise and commitment.

 

Investor/Media Contact:

David Pyrce
Chief Executive Officer
Gilboa Therapeutics
951-551-0949
david@gilboa.bio
https://www.gilboa.bio/